Establishment of a New Zealand White Rabbit Model for Lethal Toxin (LT) Challenge and Efficacy of Monoclonal Antibody 5E11 in the LT-Challenged Rabbit Model.

作者: Duanyang Zhang , Weicen Liu , Zhonghua Wen , Bing Li , Shuling Liu

DOI: 10.3390/TOXINS10070289

关键词:

摘要: Anthrax caused by Bacillus anthracis is a lethal infectious disease, especially when inhaled, and the mortality rate approaches 100% without treatment. The anthrax antitoxin monoclonal antibody (MAb) 5E11 humanized that targets protective antigen (PA). efficacy of needs proper animal models. However, spores are extremely dangerous, so experiments must be conducted under Biosafety Level 3 conditions. Considering critical effects toxin (LT) on hosts during infection, we report establishment LT-challenged rabbit model, which with dose 2 mg PA + 1 LF, while 4 LF challenge could limit death to within three days. Then, evaluated against LT. A prophylactic study showed i.v. administration 40 mg/kg four days before LT lead survival. In therapeutic studies, 10 min after provide complete protection. Overall, developed new our results indicate shows potential for clinical application in

参考文章(28)
B E Ivins, A M Friedlander, G M Zaucha, J Estep, L M Pitt, The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Archives of Pathology & Laboratory Medicine. ,vol. 122, pp. 982- 992 ,(1998)
Tao Xie, Roger D. Auth, David M. Frucht, The Effects of Anthrax Lethal Toxin on Host Barrier Function Toxins. ,vol. 3, pp. 591- 607 ,(2011) , 10.3390/TOXINS3060591
Caitlin W. Hicks, Daniel A. Sweeney, Xizhong Cui, Yan Li, Peter Q. Eichacker, An overview of anthrax infection including the recently identified form of disease in injection drug users Intensive Care Medicine. ,vol. 38, pp. 1092- 1104 ,(2012) , 10.1007/S00134-012-2541-0
Melissa Drysdale, Sara Heninger, Julie Hutt, Yahua Chen, C Rick Lyons, Theresa M Koehler, Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax The EMBO Journal. ,vol. 24, pp. 221- 227 ,(2005) , 10.1038/SJ.EMBOJ.7600495
Mahtab Moayeri, Stephen H. Leppla, Cellular and systemic effects of anthrax lethal toxin and edema toxin Molecular Aspects of Medicine. ,vol. 30, pp. 439- 455 ,(2009) , 10.1016/J.MAM.2009.07.003
Lance B. Price, Amy Vogler, Talima Pearson, Joseph D. Busch, James M. Schupp, Paul Keim, In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrobial Agents and Chemotherapy. ,vol. 47, pp. 2362- 2365 ,(2003) , 10.1128/AAC.47.7.2362-2365.2003
Nina V. Malkevich, Robert J. Hopkins, Edward Bernton, Gabriel T. Meister, Eric M. Vela, George Atiee, Virginia Johnson, Gary S. Nabors, Ronald T. Aimes, Boris Ionin, Mario H. Skiadopoulos, Efficacy and Safety of AVP-21D9, an Anthrax Monoclonal Antibody, in Animal Models and Humans Antimicrobial Agents and Chemotherapy. ,vol. 58, pp. 3618- 3625 ,(2014) , 10.1128/AAC.02295-13
Jean-Nicolas Tournier, Silvia Rossi Paccani, Anne Quesnel-Hellmann, Cosima T. Baldari, Anthrax toxins: A weapon to systematically dismantle the host immune defenses Molecular Aspects of Medicine. ,vol. 30, pp. 456- 466 ,(2009) , 10.1016/J.MAM.2009.06.002
Mahtab Moayeri, Clinton E. Leysath, Jacqueline M. Tremblay, Catherine Vrentas, Devorah Crown, Stephen H. Leppla, Charles B. Shoemaker, A Heterodimer of a VHH (Variable Domains of Camelid Heavy Chain-only) Antibody That Inhibits Anthrax Toxin Cell Binding Linked to a VHH Antibody That Blocks Oligomer Formation Is Highly Protective in an Anthrax Spore Challenge Model Journal of Biological Chemistry. ,vol. 290, pp. 6584- 6595 ,(2015) , 10.1074/JBC.M114.627943
Ju Liu, Chenguang Cai, Qiang Guo, Jun Zhang, Dayong Dong, Guanlin Li, Ling Fu, Junjie Xu, Wei Chen, Secretory expression and efficient purification of recombinant anthrax toxin lethal factor with full biological activity in E. coli Protein Expression and Purification. ,vol. 89, pp. 56- 61 ,(2013) , 10.1016/J.PEP.2013.02.012